The collaboration integrates Google Cloud’s secure cloud data architecture and machine learning into the Asensus surgical robot platform. It further expands the capabilities of Asensus’ performance-guided surgery framework through its Intelligent Surgical Unit (ISU). Research Triangle Park, North Carolina–based Asensus designed its performance-guided surgery to enhance accuracy and efficiency. The company says its platform can help surgeons avoid complications and improve patient outcomes. The I

Photo courtesy of Insulet Mass.-based insulin-pump maker Insulet acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies for $25 million. Insulet and Bigfoot offer two distinct forms of diabetes-management care: Insulet's Omnipod system that delivers insulin via a wearable, tubeless pump dubbed the Pod; and a remote controller called the Personal Diabetes Manager (PDM). Bigfoot's Unity provides injection support technologies that leverage smart pe

GE HealthCare has a vision for how it wants to shape the future of ultrasounds. The company wants ultrasound technology to be “used by nearly every clinician in nearly every situation in nearly every country around the world,” Karley Yoder, chief digital officer of GE HealthCare’s ultrasound division, said in an interview. Last week, GE HealthCare announced a deal that Yoder thinks will bring the company closer to achieving that vision. The firm unveiled its plan to acquire Caption Health, a com

近日，赛诺菲公布了2022年四季度和全年业绩，全球营收429.97亿欧元（约合453.6亿美元），同比增长13.87%，净利润68.33亿欧元，同比增长8.84%。其中处方药业务306.88亿欧元（323.76亿美元），同比增长13.8%，疫苗业务72.29亿欧元（76.27亿美元），同比增长14.3%，消耗品业务50.8亿欧元（53.59亿美元），同比增长13.7%。但考虑到欧元贬值，汇率转换后的总营收增长实际为7.0%，三大业务分别同比增长6.9%、6.3%和8.6%。处方药、疫苗和消耗品的销售成本分别为75.11亿欧元，41.01亿欧元和18.27亿欧元，毛利水平分别为77.7%，66.3%和65.3%，公司总体毛利水平为73.7%。处方药、疫苗和消耗品的研发投入强度分别为16.5%、12.9%和3.7%，公司整体研发投入67.06亿欧元，占总营收的15.6%。处方药、疫苗和消耗品的市场&管理费用分别占其销售额的19.7%，12.7%和29.1%，而公司整体水平为24.4%。处方药、疫苗和消耗品的税息前营业利润水平分别为36.0%，43.8%和35.6%。与去年同期相比，赛诺菲三

Abbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow CSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery disease ABBOTT PARK, Ill. and ST. PAUL, Minn., Feb. 8, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott

AstraZeneca’s application for a $360 million manufacturing site in a Dublin suburb is yet to be accepted, but it is making progress. The facility, which AstraZeneca first announced in 2021, will be built at an Alexion site in the suburb of Blanchardstown and produce APIs for small molecule therapies. Documents submitted to the Fingal County Council’s Planning and Strategic Infrastructure Department give more details about the project. According to the submission, the manufacturing building will

Lantheus (Nasdaq:LNTH) announced that it acquired Cerveau Technologies, a developer of a positron emission tomography imaging agent for detecting Alzheimer’s disease. Cerveau develops the MK-6240 second-generation F 18-labeled PET imaging agent. It targets Tau tangles in Alzheimer’s disease. Bedford, Massachusetts-based Lantheus intends to pay an upfront payment and potential development and commercial milestone payments. It also expects to pay double-digit royalty payments for research revenue

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers end-to-end global viral vector

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Paci

Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab) Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with